PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16437462

Melatonin for cognitive impairment.

S L Jansen·D A Forbes·V Duncan·D G Morgan
View original source ↗Export metadata ↓

Abstract

BACKGROUND: There are a number of studies that suggest a relationship between decline of melatonin function and the symptoms of dementia. OBJECTIVES: The review assessed the evidence of clinical efficacy and safety of melatonin in the treatment of manifestations of dementia or cognitive impairment (CI). SEARCH STRATEGY: The Cochrane Dementia and Cognitive Improvement Group's Specialized Register was searched for trials involving melatonin on 5 October 2005. The search terms used were MELATONIN, and N-ACETYL-5-METHOXYTRYPTAMINE. This Register contains records from all major health care databases as well as many ongoing trials databases and is updated regularly. SELECTION CRITERIA: All relevant, randomized controlled trials in which orally administered melatonin in any dosage was compared with a control group for the effect on managing cognitive, behavioural (excluding sleep), and/or affective disturbances of people with dementia of any degree of severity. DATA COLLECTION AND ANALYSIS: Two to three reviewers independently assessed the retrieved articles for relevance and methodological quality, and extracted data from the selected studies. Statistically significant differences in changes in outcomes from baseline to end of treatment between the melatonin and control groups were examined. Each study was summarized using a measure of effect (e.g. mean difference) and meta-analyses were conducted when appropriate. MAIN RESULTS: Three studies met the inclusion criteria. This review revealed non-significant effects from the pooled estimates of MMSE cognitive, and ADAS-cognitive change scores. Individual study estimates for treatment effect demonstrated a significant improvement for melatonin compared with placebo in behavioural and affective symptoms as measured by the ADAS non-cognitive scale in a study of 20 patients, and the Neuropsychiatric Inventory (NPI) following treatment with 2.5 mg/day (SR) melatonin, but not with 10mg/day (IR) melatonin in a larger study of 157 patients. The remainder of the treatment effects for affect, behaviour and activities of daily living were non-significant. AUTHORS' CONCLUSIONS: There is insufficient evidence to support the effectiveness of melatonin in managing the cognitive and non-cognitive sequelae of dementia.

Explore related subjects

AntioxidantsCognition DisordersDementiaHumansMelatoninRandomized Controlled Trials as TopicSleep Initiation and Maintenance DisordersJournal ArticleMeta-AnalysisSystematic Review

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S L Jansen, D A Forbes, V Duncan, D G Morgan. 2006-01-25. Melatonin for cognitive impairment.. https://doi.org/10.1002/14651858.cd003802.pub3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Efficacy and Safety of Low-Molecular-Weight Collagen Peptide GT for Improving Hair Condition in Individuals with Damaged Hair: A Randomized, Double-Blind, Placebo-Controlled Trial.

Addressing hair damage is essential for maintaining overall hair and scalp health. Previous studies have suggested that low-molecular-weight collagen peptides may support hair follicle biology through regulation of extracellular matrix homeostasis and cellular signaling pathways. In addition, recent preclinical studies have demonstrated that low-molecular-weight fish collagen peptides promote hair regrowth through activation of proliferative signaling and suppression of inhibitory pathways. However, their clinical efficacy in improving hair damage has not been clearly established. In this study, the efficacy and safety of low-molecular-weight collagen peptide GT (LMWCP GT) were evaluated in Korean adults with damaged hair. In a randomized, placebo-controlled trial, individuals aged 19∼60 years without alopecia but with mild to moderate hair damage received LMWCP GT (3 g/day) for 24 weeks. Compared with placebo, the treatment group demonstrated significant improvements in hair gloss, as measured using a gloss meter (SAMBA) and scanning electron microscopy, as well as in hair elasticity, assessed by tensile strength and hair diameter. Subjective evaluations further indicated improvements in overall hair condition, including gloss, elasticity, thickness, texture, fullness, and appearance. In addition, scalp elasticity was significantly increased in the treatment group. No treatment-related adverse events were observed. These findings indicate that daily supplementation with LMWCP GT (3 g/day) for 24 weeks is safe and effective in improving overall hair condition in individuals with damaged hair without alopecia.

Antioxidants↗
PubMed2026

Free polyphenols and multi-omics traits underlying antioxidant variation across Paeonia lactiflora leaf cultivars.

Leaves of Paeonia lactiflora are underutilized by-products with potential as natural antioxidant sources. In this study, 18 cultivars were evaluated for phytochemical composition and in vitro antioxidant capacity. Total phenolic content correlated strongly with DPPH and ABTS activities, and the comprehensive antioxidant index identified 'Coral Charm' and 'Hangshao' as representative high- and low-antioxidant cultivars, respectively. Untargeted metabolomics detected 2677 metabolites and identified 908 differential metabolites between the two cultivars. Targeted phenolic profiling quantified 27 compounds, among which 11 differed significantly between the two cultivars. Catechin and epicatechin were enriched in 'Coral Charm', with contents of 6.62 and 0.397 ng/mg, respectively, compared with 0.012 and 0.002 ng/mg in 'Hangshao'. (+)-Dihydroquercetin was also more abundant in 'Coral Charm', while caffeic acid showed an upward trend. Proteomic analysis identified 423 differentially expressed proteins, mainly associated with secondary metabolite biosynthesis, redox homeostasis, and central carbon metabolism. Integrated analysis identified pyruvate metabolism as the only pathway significantly enriched in both metabolomic and proteomic datasets. Molecular docking predicted favorable binding between representative phenolics and selected proteins. These findings link cultivar-dependent antioxidant variation in peony leaves with free-phenolic accumulation and pathway-level metabolic differences, supporting the selection and utilization of antioxidant-rich peony leaf resources.

Antioxidants↗
PubMed2026

A smartphone-integrated Pt@Cu-HCF nanozyme-based paper sensor for on-site determination of total antioxidant capacity in marine oils.

Total antioxidant capacity (TAC) serves as a key indicator for evaluating the nutritional quality of foods. In this study, we designed a platinum-embedded copper hexacyanoferrate (denoted as Pt@Cu-HCF) nanozyme that exhibits high oxidase-like activity, efficiently catalyzing the oxidation of chromogenic substrates to generate robust colorimetric signals. Antioxidants quench hydroxyl radicals (∙OH) produced during the catalytic process, leading to a concentration-dependent suppression of the color signal. Leveraging this mechanism, a smartphone-integrated, colorimetric paper sensor for on-site TAC quantification was developed, using vitamin E as the calibration standard. The sensor was applied to determine TAC in fish oil, algal oil, and krill oil, demonstrating a linear response range of 9.78-312.5 μM and a limit of detection (LOD) of 6.41 μM. Validation using real-world marine oil samples showed excellent agreement with a commercial assay kit, confirming the reliability and practical applicability of this portable sensor for TAC measurement in complex biological matrices.

Antioxidants↗